Bill Mezzanotte

Executive Vice President, Head of Research and Development, CSL

Appears in 1 story

Stories

CSL and Alentis partner on rare kidney and liver disease drug

Leads the lixudebart development program for CSL

CSL will pay Swiss biotech Alentis Therapeutics $355 million upfront to co-develop lixudebart, an experimental antibody for rare kidney and liver diseases. Milestones could add $1.2 billion, with profits split 55% to CSL and 45% to Alentis.

Updated Yesterday